I see a long opportunity in NVDA. Pennant in the daily chart looks to resolve by April, with Feb ER respresenting a potential catalyst. Expect testing of $600 in the coming months.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
